Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -9.00p -0.68% 1,313.00p 1,315.00p 1,316.00p 1,324.00p 1,313.00p 1,320.00p 2,584,006 16:35:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,781.0 860.0 71.3 20.2 11,490.29

Smith & Nephew Share Discussion Threads

Showing 776 to 800 of 800 messages
Chat Pages: 32  31  30  29  28  27  26  25  24  23  22  21  Older
DateSubjectAuthorDiscuss
10/9/2017
00:08
About time we had another bid story run riot in the press.
its the oxman
27/7/2017
11:02
Smith & Nephew (SN.), the medical equipment manufacturing company, reported revenue of $1,194m for the second quarter, which was flat on a reported basis and up 3% when foreign exchange headwinds and the gynaecology division disposal are excluded. The company saw a recovery in emerging markets, with revenue up 13% in the quarter. For the first half, the operating profit was $414m, up from $357m the previous year. The trading profit margin was 30 basis points higher at 21.1%, in line with guidance. The group said it continues to expect underlying revenue growth of 3-4% and a 20-70bps improvement in trading profit margin for the full year
broadwood
25/5/2017
10:06
New all time highs on an almost daily basis. And not a whisper in the press ...
mamcw
05/5/2017
09:35
Smith & Nephew said its full year outlook for underlying revenue growth remained unchanged in the 3%-4% range after posting flat first quarter revenue of $1.14bn, flat on a reported basis after -2% impact from the disposal of its gynaecology business and -1% currency headwind. Revenue was up 3% on an underlying basis for the period. Established markets, the US and other established markets revenue were all up 1%. "In Europe we are making progress improving our execution, although the slight headwinds seen last year in some European countries continued,"Smith & Nephew said. "Performance in the emerging markets was good, returning to double-digit growth, with China growing 14% in the quarter." "On a reported basis, we expect 2017 revenue growth to be in the range of 1.6%-2.6% based on prevailing exchange rates at the end of April and reflecting the 80bps headwind from the disposal of the gynaecology business," the company said.
broadwood
05/5/2017
07:26
Live bid candidate. - Smith & Nephew said its Q1 2017 trading was in line with its expectations, and that it was on track to deliver 3-4% underlying revenue growth for the FY. CEO Olivier Bohuon said that in particular the company's performance in the Emerging Markets was good, returning to double-digit growth, with China up 14% underlying. "Our innovative new products, such as the Lens camera and Werewolf Coblation systems, have been well received, and we look forward to the imminent full market release of the Total Knee Application on our Navio robotics-assisted surgery system," said Bohuon. "Over the last few years we have successfully put in place the right structures and capabilities to make the Group stronger, simpler, more agile and efficient. "We continue to focus on execution and expect to see progress through the year." Meantime, for Q1, revenue of $1.142bn was flat on a reported basis after -2% impact from Gynaecology disposal and -1% currency headwind. It was up 3% on an underlying basis. "Smith & Nephew is on-track to deliver 3-4% underlying revenue growth for full year," it said.
broadwood
10/3/2017
09:49
Now Akzo Nobel falls under the global consolidation hammer. Only a matter of time before SN is bought
mamcw
21/2/2017
15:42
Unilever situation underlines attractiveness of UK-based companies whose earnings are global to US predators.
mamcw
09/2/2017
18:58
Nice come back today. Forming a long lower wick to daily candle.
corlis
09/2/2017
17:51
sharp dip at the open but regained nearly all losses to close at 1198. it appears that someone is very keen to accumulate loose stock.
accipitridae
09/2/2017
09:37
dont forget results reflect a period when the CEO took time out for illness and also lost his CFO. SN generates loads of cash and margins are going up now.
accipitridae
09/2/2017
08:38
And down we go on a pretty lacklustre set of results.Doesn't look like we're going to see a marked acceleration in growth in 2017 given a forecast of revenue growth of around 2% and margins,whilst improving,being subject to various "headwinds"."Stryke(r) while the iron's hot" as they say and if they are to rebid,now is a opportune time when the dollar is strong and S&N have undertaken a lot of remedial action.For now,bid expectations will restrict the downside.Along with Astra Zeneca,S&N remains a slow burning fuse that has still to convince the market of its ability to resume a much improved and sustainable growth pattern.I can't help thinking though that global demographics dictates that this company must be very attractive to predators.So,I remain a strong holder.Either they get their act together or get taken over.
steeplejack
08/2/2017
22:07
ok i buy any dips
accipitridae
08/2/2017
10:56
Accipitidae sorry i meant for a LONG
corlis
08/2/2017
08:52
exactly 1200 - what does this mean
accipitridae
06/2/2017
09:24
Chart wise this at 1,200 is starting to show some promise.
corlis
01/2/2017
12:32
This looks like a fairly straightforward f/x play - with so much of S&N's sales worldwide, yet a stock market valuation that in US Dollar terms has fallen sharply, it becomes very affordable to a US based purchaser.
mamcw
26/1/2017
18:21
dont recall ever seeing a company before that is 10% below its all time highs but is actually a dog. it is a dog because it has under-performed its closest peer by 50% and look at it in dollar terms, it is 30% down over 2.5 years.
accipitridae
26/1/2017
15:48
what is the management doing about it?
accipitridae
26/1/2017
15:47
underperformed its key competitor by nearly 50%. that makes this stock a dog and therefore a good reason it should be sold.
accipitridae
26/1/2017
11:43
now J&J is tied up with Actelion could Stryker finally move on S&N ? Stryker could take advantage of the current price disparity in charts above to get S&N at bargain price. J&J Seals $30 Billion Actelion Deal in Push for Rare Disease https://www.bloomberg.com/news/articles/2017-01-26/j-jto-buy-actelion-for-30-billion-spin-off-research-operations
accipitridae
25/1/2017
17:08
but i cannot work out why. any explanations welcomed!
accipitridae
25/1/2017
17:06
nearly 50% under-performance by S&N since the beginning of last year
accipitridae
17/1/2017
08:48
ADRs surged overnight, worth about £12.64
accipitridae
22/12/2016
09:56
looks like J&J might get Actelion after all. perhaps that will enable stryker to finally make a move here? stryker has outperformed S&N by nearly 50% YTD so it could make use of its more expensive equity.
accipitridae
16/12/2016
15:16
could J&J turn in this direction if Actelion goes to Sanofi?
accipitridae
Chat Pages: 32  31  30  29  28  27  26  25  24  23  22  21  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170921 19:31:18